• Miscellaneous ocular agents

Beovu Generic Name & Formulations

General Description

Brolucizumab-dbll 6mg/0.05mL; soln for oph intravitreal inj; preservative-free.

Pharmacological Class

Vascular endothelial growth factor (VEGF) inhibitor.

How Supplied

Single-dose vial (w. needle), single-dose prefilled syringe—1

Generic Availability


Beovu Indications


Neovascular (wet) age-related macular degeneration (AMD). Diabetic macular edema (DME).

Beovu Dosage and Administration


Give by intravitreal inj. AMD: 6mg (0.05mL) once monthly (approx. 25–31 days) for the 1st 3 doses, followed by 6mg (0.05mL) once every 8–12 weeks. DME: 6mg (0.05mL) every 6 weeks (approx. 39–45 days) for the 1st 5 doses, followed by 6mg (0.05mL) once every 8–12 weeks.


Not established.

Beovu Contraindications


Ocular or periocular infections. Active intraocular inflammation.

Beovu Boxed Warnings

Not Applicable

Beovu Warnings/Precautions


Must only be administered by a qualified physician. Monitor for endophthalmitis, retinal detachments, retinal vasculitis and/or retinal vascular occlusion, elevation in IOP, and perfusion of optic nerve head following inj. Potential risk of arterial thromboembolic events (eg, nonfatal stroke or MI, vascular death). Advise females of reproductive potential to use effective contraception during and for ≥1 month after the last dose. Pregnancy. Nursing mothers: not recommended (during and for ≥1 month after the last dose).

Beovu Pharmacokinetics

See Literature

Beovu Interactions

Not Applicable

Beovu Adverse Reactions

Adverse Reactions

Vision blurred, cataract, conjunctival hemorrhage, eye pain, vitreous floaters; hypersensitivity reactions.

Beovu Clinical Trials

See Literature

Beovu Note

Not Applicable

Beovu Patient Counseling

See Literature